AMERICAS
Latin America continues to dominate this region, with Mexico and Brazil being the most significant contributors to the region’s performance. There is one manufacturing site in this region which is situated in Brazil and which focuses on finished dose form (“FDF”). The region commercialises internationally recognised medicines across the prescription, hospital and over-the-counter (“OTC”) channels.
Key Countries
Brazil
Canada
Chile
Colombia
Ecuador
Mexico
USA
KEY BRANDS
Brand | Therapeutic category | |
Diprivan | General anaesthetic | |
Meticorten | Corticosteroid | |
Milk of Magnesia | Antacids-antiflatulants | |
Perfalgen | Analgesic injectable | |
Xylocaine | Regional anaesthetic |
NUMBER OF PERMANENT EMPLOYEES
714
June 2022
768
June 2021

STATISTICS
Number of products launched:
20
(2021: 3)
Number of product recalls:
1
(2021: 1)
Average staff turnover:
22%
(2021: 14%)
Number of work-related fatalities:
Nil
(2021: Nil)
Sales representatives:
235
(2021: 235)
Revenue | 2022 R’million |
2021 (CER) R’million |
Change % |
||||
---|---|---|---|---|---|---|---|
Commercial Pharmaceuticals | |||||||
Regional Brands | 2 856 | 2 636 | 8 | ||||
Sterile Focus Brands | 1 439 | 1 400 | 3 | ||||
Total | 4 295 | 4 036 | 6 |
Note: Commercial Pharmaceuticals revenue is by customer geography.
- The Mexican pharmaceutical market grew 8% to EUR9,01 billion MAT June 2022, positively impacted by growth across the generic, ethical and OTC markets.
- Pharmaceutical sales across the total Spanish Latin America market grew 13,6% to EUR22,5 billion MAT June 2022.
Source: IQVIA – June 2022
MAT= Moving annual total